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Abstract
Background: Lichenoid drug eruption is rare and can mimic idiopathic lichen planus and other dermatoses.
Clonazepam, a commonly used drug for the treatment of anxiety-related disorders and seizures, is known to be an
unlikely cause of cutaneous adverse effects. Only one case report of LDE due to clonazepam has been reported.
Case presentation: A 81-year-old male patient with Alzheimer’s disease developed a lichenoid eruption after taking
clonazepam. He developed a violaceous scaly patch on his lower extremities, from both buttocks to the feet. The
cutaneous eruption resolved 2months after cessation of clonazepam and with initiation of corticosteroid therapy.
Conclusion: A skin eruption that develops after clonazepam administration can be a lichenoid drug eruption, which is
less likely to resolve spontaneously and requires discontinuation of clonazepam administration.
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Background
Drug eruption is the most common adverse drug
reaction. The list of conditions that can be triggered by
medications includes nearly all dermatological diseases,
ranging from mild and moderate such as pruritus and
lichenoid eruptions to severe ones like Stevens-Johnson
syndrome [1]. Lichenoid drug eruption (LDE) is a rare
type of drug eruption that can resemble idiopathic lichen
planus (LP) clinically and histopathologically. LDE is in-
duced by various drugs, such as gold salts, antimalarial
drugs, β-blockers, angiotensin-converting-enzyme inhibi-
tors [2]. Clonazepam is one of the most commonly used
drugs for treating anxiety-related disorders and seizures.
Common side effects such as drowsiness and sedation
are well known and can be appropriately considered by
clinicians. However, rare hypersensitivity reactions and
cutaneous adverse effects are difficult to consider in
most clinical situations and only one case report of LDE
due to clonazepam has been reported [3, 4].
In the current case report, we present an 81-year-old
Alzheimer’s disease (AD) patient with LDE induced by
clonazepam. We aim to increase the clinicians’ insights
into a rare drug eruption, and importance of early
identification of the offending drug which may reduce
unnecessary discomfort in patients due to delayed
diagnosis.
Case presentation
An 81-year-old man with 3 to 4 years of slowly progres-
sive memory impairment visited the clinic for evaluation.
The patient reported difficulty in recalling where he
placed objects, and difficulty in understanding news
programs. Except for memory impairment, other cognitive
domains such as language, orientation, judgment, person-
ality, and behavior were intact. In neuropsychological
tests, he showed poor performance in word list recall and
recognition, below − 2 standard deviation, while the scores
in other cognitive domains were within the normal limit.
He was receiving long-term treatment with enalapril for
hypertension and had no other diseases or medications.
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He had a history of regular alcohol consumption (2 stand-
ard drinks per day) for 56 years, and had quit smoking 30
years ago. Detailed physical and neurological examinations
did not reveal any abnormality. His blood tests were
normal except for mild hypercholesterolemia. Magnetic
resonance imaging (MRI) showed diffuse brain atrophy
and bilateral hippocampal atrophy. Medial temporal lobe
scores were 1/2 each on the left and right according to the
Skeltens scale [5]. According to the Fazekas scale, the
rating of white matter hyperintensities was 2 on the peri-
ventricular white matter and 1 on the deep white matter
[6]. A positron emission tomography (PET) scan showed
diffuse hypometabolism in the left frontoparietal cortices.
Based on clinical findings and imaging biomarkers, he was
diagnosed with mild cognitive impairment due to AD ac-
cording to the diagnostic criteria proposed by the National
Institute on Aging-Alzheimer’s Association (NIA-AA) [7].
Donepezil was started at 2.5 mg/day, escalating to 10mg/
day over several months. At 18months, he had difficulty
with nighttime sleep, and clonazepam 0.25mg/day was
started.
Three weeks after starting clonazepam, the patient
visited the dermatology outpatient clinic in our hospital
with itchy eruptions on the lower extremities. His skin
lesions had already improved to some extent by self-
applying steroid ointment 3 days before. Because he had
suffered from unspecified dermatitis for a long time and
there was no history of allergy or drug reaction, a drug
eruption was not suspected at the time. Since the lesions
started to resolve, he was decided to follow up without
special treatment, and only a p.r.n. topical steroid was
prescribed. Since then, the lesions did not fully remit but
rather spread, and the patient re-visited after 4 months.
Physical examination revealed a violaceous scaly patch
on the lower extremities, from both buttocks to feet
(Fig. 1a,b). For further evaluation, laboratory tests and
tissue biopsy were performed. His eosinophil count was
slightly elevated to 7.1%, while other laboratory values
were within the normal range. The histopathological
findings of the eruptions on the left lower leg showed a
lichenoid dermatitis pattern (Fig. 2). Based on clinical
and histopathological findings, clonazepam-induced LDE
was most strongly suspected. Clonazepam was discontin-
ued, and zolpidem was prescribed for sleep control.
Additionally, he was treated with a week of oral steroids
and tacrolimus 0.1% ointment.
Although new lesions appeared on the upper extrem-
ities, most of the existing lesions gradually improved
1 month after clonazepam was discontinued. All eruptions
disappeared over the next month and there was no recur-
rence after that. Sleep was well controlled by intermittent
administration of zolpidem, and no more benzodiazepine
was prescribed, including clonazepam. Memantine was
added due to progressive cognitive decline, but no adverse
reaction occurred.
Discussion and conclusions
In the current case, LDE developed in patients with
preexisting dermatitis after taking clonazepam, and it
was improved over several months after cessation of the
drug. Clonazepam is commonly prescribed for treating a
range of disorders for which it had not originally been
approved, including sleep-related disorders, withdrawal
from other benzodiazepines, and pain management [8].
Clonazepam has been rarely associated with cutaneous
adverse reactions, and only a few cases, such as ery-
thema multiforme, pseudo-mycosis fungoides, localized
exfoliating eruptions, alopecia, bullous dermatosis, and
eczematous drug eruption have been reported [9–14].
To the best of our knowledge, only two case reports of
LDE due to clonazepam has been reported [4, 15].
Cutaneous adverse effects of clonazepam are idiosyn-
cratic and have been reported in a few patients taking
various doses ranging from 0.5 to 2 mg/day [9–14]. Only
one patient developed an LDE with clonazepam; how-
ever, this patient’s dosage was not stated [4]. Our patient
with clonazepam-induced lichenoid eruption was treated
at 0.25 mg/day. The incidence of LDE was known to be
Fig. 1 Violaceous scaly patch on the left foot (a) and both lower legs (b)
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dependent on the causative drug rather than the dose
[2]. LDE is less likely to resolve spontaneously and may
require cessation of the offending agent in addition to
corticosteroid therapy [16]. Therefore, in the case of
clonazepam-induced LDE, it may be reasonable to
discontinue the drug rather than to consider dose
reduction.
LDE seems to have a long latent period of 4 weeks to
3 years, while the latent period of most drug eruptions is
about 1 or 2 weeks, or up to 1 month. The identification
of the offending drug can be complicated by such
variability in the latent period between intake of a drug
and appearance of the eruption. The latent period may
vary depending on the offending drug, the dosage of the
drug, and the patient’s individual reaction to the drug.
The length of the resolution also depends on the offend-
ing drug, and it may be up to 5 months [2]. In our case,
it was difficult to determine the onset of LDE due to
comorbid dermatitis, but the latent period may be esti-
mated from about 3 weeks to 4 months. After clonaze-
pam was discontinued, it took 2 months for the lesions
to disappear, which was in line with the typical course of
LDE.
In the current case, the patient has also taken enalapril
and lichen planus-like eruptions induced by enalapril
have been reported a few times in the literature [17–19].
The contribution of clonazepam and enalapril in our
patient’s development of LDE was evaluated by using
the Naranjo Adverse Drug Reaction (ADR) Probability
Scale [20], which revealed the probable influence of
clonazepam and the possible influence of enalapril in
LDE development. Therefore, it may be presumed that
clonazepm had a higher impact on LDE development
than enalapril. In addition, previous literatures reported
that lichen planus-like eruption due to enalapril
appeared between 6 weeks and 6months [17–19]. In our
case, enalapril had been taken for 11 years, which was
less likely to cause LDE because it is much longer than
the longest reported latent period.
Cytochrome P-450 including CYP3A, may play an
important role in clonazepam metabolism. There is no
evidence that clonazepam induces its own metabolism
or that of other drugs in humans [3]. Enalapril is pro-
drugs metabolized in the liver, and some animal studies
provide information suggesting that prodrugs seem to
undergo CYP3A4-dependent biotransformation. However,
the angiotensin-converting enzyme inhibitors including
enalapril are not involved in significant cytochrome P450–
mediated interactions with other drugs [21]. Therefore, a
clinically significant interaction was not strongly expected.
Similar to other forms of drug eruptions, withdrawal
of the suspected drug followed by the disappearance of
the lichenoid eruption may confirm the diagnosis of
LDE [2]. In this case, the course of rash disappearance
after cessation of clonazepam was clear, so it was pos-
sible to diagnose clonazepam-induced LDE. As in the
previously reported case, the most confirmative way to
determine the causative drug may be to ascertain the
disappearance of the eruption after cessation of the sus-
pected drug and to reproduce the eruption by re-
administering the drug [4]. However, re-exposure of the
offending drug for diagnosis only may be dangerous and,
therefore, not recommended. Topical provocation tests,
which were not performed in our case, are safer, while it
is known to have a higher false-negative rate [2, 22].
In conclusion, although it is not frequent, clonazepam
may cause drug eruptions, such as LDE. Therefore, if
eruptions appear after newly prescribed clonazepam, a
thorough history taking and investigations should be
performed, and if necessary, changing the drug and
referencing to a dermatologist are advised.
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